title: Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature.
abstract: Some dental materials and certain drugs may induce epithelial alterations, which clinically resemble oral lichen planus (OLP), on oral mucosa. But these alterations do not have all the clinical and/or the histological features of OLP; these lesions are known as oral lichenoid lesions (OLLs). Some researchers describe the onset and/or the worsening of OLL/OLP after the administration of anti-hepatitis C virus (HCV) therapy. In this article, we describe the development of symptomatic OLLs, as a consequence of anti-HCV therapy (interferon-alpha and ribavirine), in 2 human immunodeficiency virus-HCV-coinfected subjects. An immunological cause related to coinfection and administration of different medications could be responsible for the onset of OLLs. These new cases, together with the previous reports of a possible association between OLP and/or OLL and anti-HCV therapy, highlight the absolute need to monitor carefully the human immunodeficiency virus-HCV-coinfected subjects who are about to start the anti-HCV therapy and to define better the clinical and histopathological criteria to distinguish OLP from OLL.
authors.affiliation: School of Dentistry, Catholic University, Rome, Italy. michele.giuliani@rm.unicatt.it
authors.forename: Michele
authors.initials: M
authors.lastname: Giuliani
authors.forename: Carlo
authors.initials: C
authors.lastname: Lajolo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Sartorio
authors.forename: Michele
authors.initials: M
authors.lastname: Scivetti
authors.forename: Saverio
authors.initials: S
authors.lastname: Capodiferro
authors.forename: Mario
authors.initials: M
authors.lastname: Tumbarello
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D017676:Lichen Planus, Oral / Q000175:diagnosis / Q000473:pathology; D017512:Lichenoid Eruptions / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D009061:Mouth Mucosa / Q000473:pathology; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin